文献速递系统性红斑狼疮

缓解与低疾病活动度与较低的医疗费用相关:来自系统性红斑狼疮国际协作诊所(SLICC)起始队列的结果

Remission and low disease activity are associated with lower healthcare costs: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.
PubMed 文献 · Ann Rheum Dis · 2024-09-30

该多中心起始队列纳入10国31中心1692例系统性红斑狼疮患者,平均随访9.7年,49.0%的评估为活动状态。与活动状态相比,处于缓解或低疾病活动度状态的时间每增加25%,年度直接和间接费用均较低;各缓解/低疾病活动度状态之间无费用差异。

要点

  • 缓解或低疾病活动度状态时间每增加25%,年度直接费用降低$C973至$C1372。
  • 缓解或低疾病活动度状态时间每增加25%,年度间接费用降低$C2507至$C2604。
  • 各缓解/低疾病活动度状态之间无费用差异。

核心结论

  • 数据提示,实现缓解(无论是否用药)及疾病活动度降低的系统性红斑狼疮患者,其费用低于持续疾病活动者。

研究设计与样本

  • 多中心起始队列研究,纳入10个国家31个中心的患者,在诊断后15个月内入组并每年评估。
  • 共1692例患者,平均随访9.7年,49.0%的评估为活动状态。

主要发现

  • 与活动状态相比,处于缓解或低疾病活动度状态的时间每增加25%,年度直接费用和间接费用均较低。
  • 无治疗缓解:直接费用-$C1372,间接费用-$C2507。
  • 治疗中缓解:直接费用-$C973,间接费用-$C2604。
  • LDA-TC:直接费用-$C1158;mLLDAS:直接费用-$C1040。
  • 各缓解/低疾病活动度状态之间无费用差异。

关键数值与推荐

  • 无治疗缓解:cSLEDAI-2K=0,且未使用泼尼松/免疫抑制剂。
  • 治疗中缓解:cSLEDAI-2K=0,泼尼松≤5 mg/天和/或维持性免疫抑制剂。
  • LDA-TC:cSLEDAI-2K≤2,且未使用泼尼松/免疫抑制剂。
  • mLLDAS:SLEDAI-2K≤4,主要器官/系统无活动,无新发活动,泼尼松≤7.5 mg/天和/或维持性免疫抑制剂。
  • 活动状态:所有其余评估。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aims to determine the independent impact of definitions of remission/low disease activity (LDA) on direct/indirect costs (DCs, ICs) in a multicentre inception cohort. METHODS: Patients from 31 centres in 10 countries were enrolled within 15 months of diagnosis and assessed annually. Five mutually exclusive disease activity states (DAS) were defined as (1) remission off-treatment: clinical (c) SLEDAI-2K=0, without prednisone/immunosuppressants; (2) remission on-treatment: cSLEDAI-2K=0, prednisone ≤5 mg/day and/or maintenance immunosuppressants; (3) LDA-Toronto Cohort (TC): cSLEDAI-2K≤2, without prednisone/immunosuppressants; (4) modified lupus LDA state (mLLDAS): SLEDAI-2K≤4, no activity in major organs/systems, no new activity, prednisone ≤7.5 mg/day and/or maintenance immunosuppressants and (5) active: all remaining assessments.At each assessment, patients were stratified into the most stringent DAS fulfilled and the proportion of time in a DAS since cohort entry was determined. Annual DCs/ICs (2021 Canadian dollars) were based on healthcare use and lost workforce/non-workforce productivity over the preceding year.The association between the proportion of time in a DAS and annual DC/IC was examined through multivariable random-effects linear regressions. RESULTS: 1692 patients were followed a mean of 9.7 years; 49.0% of assessments were active. Remission/LDA (per 25% increase in time in a remission/LDA state vs active) were associated with lower annual DC/IC: remission off-treatment (DC -$C1372; IC -$C2507), remission on-treatment (DC -$C973; IC -$C2604,) LDA-TC (DC -$C1158) and mLLDAS (DC -$C1040). There were no cost differences between remission/LDA states. CONCLUSIONS: Our data suggest that systemic lupus erythematosus patients who achieve remission, both off and on-therapy, and reductions in disease activity incur lower costs than those experiencing persistent disease activity.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Barber MRW, Ugarte-Gil MF, Hanly JG, et al. Remission and low disease activity are associated with lower healthcare costs: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Ann Rheum Dis. 2024. PMID: 38754981. doi:10.1136/ard-2024-225613

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。